Journal
JOURNAL OF VIROLOGY
Volume 86, Issue 5, Pages 2632-2640Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.05416-11
Keywords
-
Categories
Funding
- Postgraduate Research Participation Program
- U. S. Army Research and Medical Command
- NIH [P41 GM086180]
Ask authors/readers for more resources
Orthopoxviruses include the prototypical vaccinia virus, the emerging infectious agent monkeypox virus, and the potential bio-threat variola virus (the causative agent of smallpox). There is currently no FDA-approved drug for humans infected with orthopoxviruses. We screened a diversity-oriented synthesis library for new scaffolds with activity against vaccinia virus. This screen identified a nonnucleoside analog that blocked postreplicative intermediate and late gene expression. Viral genome replication was unaffected, and inhibition could be elicited late in infection and persisted upon drug removal. Sequencing of drug-resistant viruses revealed mutations predicted to be on the periphery of the highly conserved viral RNA polymerase large subunit. Consistent with this, the compound had broad-spectrum activity against orthopoxviruses in vitro. These findings indicate that novel chemical synthesis approaches are a potential source for new infectious disease therapeutics and identify a potentially promising candidate for development to treat orthopoxvirus-infected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available